Sosei Acquires Heptares Therapeutics for $180 Million

Japan’s Sosei have announced today that they have acquired Heptares Therapeutics, a UK based biotechnology company, in a deal that could be worth up to $400 million. Heptares Therapeutics specialises in creating medicines targeting G protein-coupled receptors (GPCRs).  Sosei have agreed to pay $180 million of that upfront to gain access to Heptares’ GPCRs, a

Continue Reading